Alterations of Fas (Apo-1/CD95) gene in cutaneous malignant melanoma

American Journal of Pathology

Volumn 154, Issue 6, 1999, Pages 1785-1791

  Shin, Min Sun ^a   Park, Won Sang ^a   Kim, Su Young ^a   Kim, Ho Sik ^a   Kang, Seok Jin ^a   Song, Kye Yong ^b   Park, Jik Young ^a   Dong, Seung Myung ^a   Pi, Jae Ho ^a   Oh, Ro Ra ^a   Lee, Jung Young ^a   Yoo, Nam Jin ^a   Lee, Sug Hyung ^a  

^a The Catholic University of Korea   (South Korea)

^b Chung Ang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

FAS ANTIGEN;

ANTIGEN EXPRESSION; ARTICLE; DNA SEQUENCE; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MELANOMA; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 0000293602     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65434-X     Document Type: Article

References (41)

1. Nagata S: Apoptosis by death factor. Cell 1997, 88:355-365
2. Itoh N, Nagata S: A novel protein domain required for apoptosis: mutational analysis of human Fas antigen. J Biol Chem 1993, 268: 10932-10937
3. Itoh N, Yonehara S, Ishii A, Yonehara M, Mizushima S, Sameshima M, Hase A, Seto Y, Nagata S: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 1991, 66:233-243
4. Leithäser F, Dhein J, Mechtersheimer G, Koretz K, Brüderlein S, Henne C, Schmidt A, Debatin K-M, Krammer PH, Möller P: Constitutive and induced expression of APO-1, a new member of the new growth factor/tumor necrosis receptor superfamily, in normal and neoplastic cells. Lab Invest 1993, 69:415-429
5. Suda T, Takahashi T, Golstein P, Nagata S: Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell 1993, 75:1169-1178
6. Suda T, Nagata S: Purification and characterization of the Fas-ligand that induces apoptosis. J Exp Med 1994, 179:873-879
7. Trauth BC, Klas C, Peters AMJ, Matzku S, Möller P, Falk W, Debatin KM, Krammer PH: Monoclonal antibody-mediated tumor regression by induction of apoptosis. Science 1989, 245:301-305
8. Yonehara S, Ishii A, Yonehara M: A cell-killing monoclonal antibody (anti-Fas) to a cell surface antigen co-downregulated with the receptor of tumor necrosis factor: J Exp Med 1989, 169:1747-1756
9. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S: Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responses. Cancer Res 1994, 54:1580-1586
10. Natoli G, Ianni A, Costanzo A, Petrillo GD, Ilari I, Chirillo P, Balsano C, Levrero M: Resistance to Fas-mediated apoptosis in human hepatoma cells. Oncogene 1995, 11:1157-1164
11. Hughes SJ, Nambu Y, Soldes OS, Hamstra D, Rehemtulla A, Iannettoni MD, Orringer MB, Beer DG: Fas/APO-1 (CD95) is not translocated to the cell membrane in esophageal adenocarcinomas. Cancer Res 1997, 57:5571-5576
12. Nambu Y, Hughes SJ, Rehemtula A, Hamstra D, Orringer MB, Beer DG: Lack of cell surface Fas/APO-1 expression in pulmonary adenocarcinomas. J Clin Invest 1998, 101:1102-1110
13. Bennett M, Macdonald K, Chan S-W, Luzio JP, Simari R, Weissberg P: Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-293
14. Sato T, Irie S, Kituda S, Reed JC: FAP-1: a protein tyrosine phosphatase that associates with Fas. Science 1995, 268:411-415
15. Irmler M, Thome M, Hahne M, Schneider P, Hofmann K, Steiner V, Bodmer JL, Burns K, Mattmann C, Rimoldi D, French LE, Tschopp J: Inhibition of death receptor signals by cellular FLIP. Nature 1997, 388:190-195
16. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S: Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 1992, 356:314-317
17. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, Strober W, Lenardo MJ, Puck JM: Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995, 81:935-946
18. Rieux-Laucat F, Le Deist F, Hivroz C, Roberts IAG, Debatin KM, Fischer A, de Villarty JP: Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science 1995, 268: 1347-1349
19. Drappa J, Vaishnaw AK, Sullivan KE, Chu JL, Elkon KB: Fas gene mutations in the Canale-Smith syndrome, an inherited lymphoproliferative disorder associated with autoimmunity. N Engl J Med 1996, 335:1643-1649
20. Bettinardi A, Brugnoni B, Quiros-Roldan E, Malagoli A, Grutta SL, Correra A, Notarangelo LD: Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood 1997, 89:902-909
21. Infante AJ, Britton HA, DeNapoli T, Middelton LA, Lenardo MJ, Jackson CE, Wang J, Fleisher T, Straus SE, Puck JM: The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis. J Pediatr 1998, 133:629-633
22. Landowsky TH, Qu N, Buyuksal I, Painter JS, Dalton WS: Mutations in the Fas antigen in patients with multiple myeloma. Blood 1997, 90: 4266-4270
23. Beltinger C, Kurz E. Bohler T, Schrappe M, Ludwig WD, Debatin KM: CD 95 (APO-1/Fas) mutations in childhood T-lineage acute lymphoblastic leukemia. Blood 1998, 91:3943-3951
24. Tamiya S, Etoh KI, Suzushima H, Takatsuki K, Matsuoka M: Mutation of CD 95 (Fas/APO-1) gene in adult T-cell leukemia cells. Blood 1998, 91:3935-3942
25. Grønbæk K, Straten PT, Ralfkiaer E, Ahrenkiel V, Andersen MK, Hansen NE, Zeuthen, J, Hou-Jensen K, Guldberg P: Somatic Fas mutations in non-Hodgkin's lymphoma: association with extranodal disease and autoimmunity. Blood 1998, 92:3018-3024
26. Davidson WF, Giese T, Fredrickson TN: Spontaneous development of plasmacytoid tumors in mice with defective Fas-Fas ligand interactions. J Exp Med 1998, 187:1825-1838
27. Rivoltini L, Radrizzani M, Accornero P, Squarcina P, Chiodoni C, Mazzocchi A, Castelli C, Tarsini P, Viggiano V, Belli F, Colombo MP, Parmiani G: Human melanoma-reactive CD4+ and CD8+ CTL clones resist Fas ligand-induced apoptosis and use Fas/Fas ligand-independent mechanisms for tumor killing. J Immunol 1998, 161:1220-1230
28. Thomas WD, Mersey P: CD4 T cells kill melanoma cells by mechanisms that are independent of Fas (CD95). Int J Cancer 1998, 75: 384-390
29. Healy E, Belgaid C, Takata M, Harrison D, Zhu NW, Burd DA, Rigby HS, Matthews JN, Rees JL: Prognostic significance of allelic losses in primary melanoma. Oncogene 1998, 16:2213-2218
30. Healy E, Belgaid CE, Takata M, Vahlquist A, Rehman I. Rigby H, Rees JL: Allelotypes of primary cutaneous melanoma and benign melanocytic nevi. Cancer Res 1996, 56:589-593
31. Walker GJ, Palmer JM, Walters MK, Hayward NKA: Genetic model of melanoma tumorigenesis based on allelic losses. Genes Chromosomes Cancer 1995, 12:134-141
32. Isshiki K, Elder DE, Guerry D, Linnenbach AJ: Chromosome 10 allelic loss in malignant melanoma. Genes Chromosomes Cancer 1993, 8:178-184
33. Lee JY, Dong SM, Kim SY, Yoo NJ, Lee SH, Park WS: A simple, precise, and economical microdissection technique for analysis of genomic DNA from archival tissue sections. Virchows Arch 1998, 433:305-309
34. Fiucci G, Ruberti G: Detection of polymorphisms within the Fas cDNA gene sequence by GC-clamp denaturing gradient gel electrophoresis. Immunogenetics 1994, 39:437-439
35. Huang QR, Morris D, Manolios N: Identification and characterization of polymorphisms in the promoter region of the human Apo-1/fas (CD95) gene. Mol Immunol 1997, 34:577-582
36. Lee SH, Kim SY, Lee JY, Shin MS, Dong SM, Na EY, Park WS, Kim KM, Kim CS, Kim SH, Yoo NJ: Detection of soluble Fas using in situ reverse transcription-polymerase chain reaction. Lab Invest 1998, 78:453-459
37. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas, and initiates apoptosis. Cell 1995, 81:505-512
38. Yang X, Khosravi-Far R, Chang HY, Baltimore D: Daxx, a novel Fas-binding protein that activates JNK, and apoptosis. Cell 1997, 89:1067-1076
39. Oishi M, Maeda K, Sugiyama S: Distribution of apoptosis-mediating Fas antigen in human skin and effects of anti-Fas monoclonal antibody on human epidermal keratinocytes and squamous cell carcinoma cell lines. Arch Dermatol Res 1994, 286:396-407
40. Kanter-Lawensohn L, Hedblad MA, Wejde J, Larsson O: Immunohistochemical markers for distinguishing Spitz nevi from malignant melanomas. Mod Pathol 1997, 10:917-920
41. ̈ornig M, Grzeschiczek A, Kowalski M-B, Hartmann K-U, Möröy T: Loss of Fas/APO-1 receptor accelerates lymphomagenesis in Eμ L-MYC transgenic mice but not in animals infected with MoMuLV, Oncogene 1995, 10:2397-2401